Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET

Japanese Journal of Clinical Oncology

Volumn 43, Issue 3, 2013, Pages 337-341

  Furuse, Motomasa ^a   Nonoguchi, Naosuke ^a   Kawabata, Shinji ^a   Yoritsune, Erina ^a   Takahashi, Masatsugu ^a   Inomata, Taisuke ^a   Kuroiwa, Toshihiko ^a   Miyatake, Shin Ichi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Bevacizumab; Brain edema; Karnofsky performance status; Positron emission tomography; Radiation necrosis

Indexed keywords

4 BORONOPHENYLALANINE; BEVACIZUMAB; FLUORINE 18;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; NON INVASIVE PROCEDURE; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RADIATION NECROSIS;

ADULT; AGED; AMINO ACIDS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NECROSIS; RADIATION INJURIES; RADIOTHERAPY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84874814050     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys231     Document Type: Article

References (16)

1. Furuse M, Kawabata S, Kuroiwa T, Miyatake SI. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 2011;102:471-5.
2. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007;67:323-6.
3. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011;79:1487-95.
4. Torcuator R, Zuniga R, Mohan YS, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009;94:423-31.
5. Miyashita M, Miyatake S, Imahori Y, et al. Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas. J Neurooncol 2008;89:239-46.
6. Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-D,L-phenylalanine: a target compound for PET and boron neutron capture therapy. Int J Rad Appl Instrum 1991;42:325-8.
7. Mishima Y, Imahori Y, Honda C, et al. In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue. J Neurooncol 1997;33:163-9.
8. Imahori Y, Ueda S, Ohmori Y, et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 1998;39:325-33.
9. Takahashi Y, Imahori Y, Mineura K. Prognostic and therapeutic indicator of fluoroboronophenylalanine positron emission tomography in patients with gliomas. Clin Cancer Res 2003;9:5888-95.
10. Li YQ, Ballinger JR, Nordal RA, Su ZF, Wong CS. Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res 2001;61:3348-54.
11. Nonoguchi N, Miyatake SI, Fukumoto M, et al. The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: Pathological consideration of their potential roles. J Neurooncol 2011;105:423-31.
12. Miyatake S, Kawabata S, Kajimoto Y, et al. Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 2005;103:1000-9.
13. Miyatake SI, Kawabata S, Nonoguchi N, et al. Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro Oncol 2009;11:430-6.
14. Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008;49:694-9.
15. Nariai T, Ishiwata K, Kimura Y, et al. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiat Isot 2009;67: S348-50.
16. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010;16:269-78.